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To the Editor: The role of MHC class II expression by pancreatic beta cells in Type 1 diabetes is of central interest to our understanding of the autoimmune process and is a highly controversially issue, which has been discussed for the past two decades. In a recent publication, we showed that beta cells from non-obese diabetic (NOD) mice express MHC class II protein and that the frequency of beta cells positive for I-A g7 mRNA strongly increases during progression to overt hyperglycaemia. We proposed that this MHC class II expression by beta cells may make them a direct target of autoreactive CD4+ T cells and that this may be a critical disease-promoting event [1] .
Some years ago, D. W. R. Gray developed an intellectually very attractive theory of the "MHC-based inhibition of autoreactive cells (MIAC)" [2] , which postulates rather the opposite. The MIAC theory "is a reversal of previous concepts of the role of MHC molecules in autoimmune disease. Instead of being seen as the activators of abnormal immune activity, MHC molecules are instead seen as providing a necessary down-regulatory signal that normally prevents autoreactivity." The MIAC theory postulates that in "Type 1 diabetes it is the inability of beta cells to deliver sufficient negative signal from MHC class II that drives the underlying autoimmune process". Furthermore Gray suggests that "the crucial question is whether the MHC expression of beta cells is inappropriately low at the point of initiation of autoimmune attack in affected individuals" [2] .
In a comment on our paper, D. W. R. Gray states that at time points when "the immune destructive process was well under way", we did not detect MHC class II protein, but "only in samples taken at 11 weeks or more, shortly before the onset of actual diabetes." In other words, Gray assumes that we were unable to detect MHC class II protein at the point of initiation of the autoimmune attack due to a low level of expression, a level too low to deliver an appropriate negative signal for "switching-off" autoreactive T cells. In conclusion, he suggests that our findings are in precise agreement with his "MIAC" theory [3] .
Replying to his comment, we would like to mention the following points. Firstly, we did not analyse MHC class II expression by NOD beta cells at earlier time points than 11 weeks of age. Our aim was to complement the data on the kinetics of MHC class II mRNA expression by beta cells by showing that these cells also express the corresponding protein. After the procedure of generating an islet single cell suspension, fixation, surface staining, permeabilisation and intracellular staining, only a few insulin-positive cells remained available for analysis on the coverslips. This was why we chose 11-weekold mice, in which the autoimmune process has not already destroyed too many beta cells, and in which the frequency of beta cells expressing MHC class II mRNA is relatively high. It cannot, thus, be concluded that we showed retarded MHC class II protein expression compared to the expression of the corresponding mRNA (which would support the MIAC theory).
More importantly, if autoimmunity were indeed normally prevented by an inhibitory or negative signal delivered by MHC class II molecules, one would, in an appropriate inflammatory environment, expect non-haematopoietic cells to be MHC-class-II-positive. However, MHC class II expression by tissue cells is the exception rather than the rule. But perhaps tissue cells have not yet been analysed sufficiently under appropriate conditions, i.e. in an environment where beta cells express MHC class II protein?
We not only studied I-A g7 protein expression by single cell multiplex immunofluorescence, but also by classical immunohistochemistry. As shown in Figure 1 , I-A g7 is expressed by beta cells of a 15-week-old female NOD mouse (insulin staining of a consecutive section not shown), even though these cells are not in the direct vicinity of cytokine-releasing infiltrating cells (arrows a). In contrast, cells of the exocrine pancreas directly adjacent to infiltrating cells are virtually negative for MHC class II (arrows b). Thus, in an autoimmune/inflammatory setting, target cells of the autoimmune destruction are positive, and protected cells negative for MHC class II. It was on the basis of this observation that in the discussion of our findings we ascribed a disease-promoting rather than a diseaseinhibiting role to MHC class II expression by beta cells. To the Editor: Gastaldelli and co-workers [1] report an analysis of cross-sectional OGTT and euglycaemic clamp data from a sample with varying glucose tolerance (NGT, IGT, Type 2 diabetes) and conclude that "...beta cells in obese individuals function in an identical fashion to those of lean individuals." This conclusion is supported by a lack of effect of obesity on the strong correlations between the insulin secretion/insulin resistance Index ( Disposition Index [2]) and the fasting or 2-h glucose concentrations of the subjects studied. This conclusion appears inconsistent with our recent finding that baseline adiposity predicts reduced beta cell function at 6-year follow up, and does so independently of diabetes risk status [3] . However, we would suggest that there is no real inconsistency between the two studies, as the conclusions of Gastaldelli and colleagues are based on spurious correlations. Fasting and 2-hour glucose levels are themselves determined by beta cell function and insulin sensitivity, so that the relationships obtained in the study in question are predominantly the result of plotting the Index against an inverse function of itself.
To illustrate this point, consider the simple one-pool model of glucose dynamics which is implicit in the calculation of the Index:
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